PatientsVille.com LogoPatientsVille.com

Overactive Bladder | Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome

Overactive Bladder research study

What is the primary objective of this study?

OAB is a widespread medical problem affecting 6- 30% of the population (both sexes and all age groups) in Europe1 and 16%2-18%3 of the US and Canadian population. Nevertheless only a small proportion of this group turns to seek medical help. Once treated, evaluation of treatment outcome is problematic since outcome measures for success vary widely (i.e. improvement in number of incontinence episodes, number of urge episodes, change in frequency and nocturia etc) but do not include measures of patient reported outcomes. The OAB Assessment Tool is a self-administered questionnaire (8-question self–filled survey) primarily intended to identify patients with symptoms of OAB. The same comparable information could be obtained after a certain treatment period, thus providing accurate and precise measures of success. It could also offer insight to the changes of the different parameters that make up the problem. Due to its ease of administration and its high specificity in assessing OAB, the OAB Assessment Tool seems to be optimal for this objective.

Who is eligible to participate?

Inclusion Criteria: 1. OAB score of ≥ 8 2. Age 20-80 years old 3. Patients must comply and agree to the requirement of taking only Detrusitol 4mg and no other new medication affecting the lower urinary tract system Exclusion criteria: 1. Patients that are on any other treatment (whether medical or conservative) for OAB. 2. Patients with documented UTI. 3. Patients who have demonstrated hypersensitivity to the drug or its ingredients. 4. Where Detrusitol is contraindicated (i.e. patients with severe outlet obstruction, gastric retention, or uncontrolled narrow-angle glaucoma).

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Overactive Bladder

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:DETRUSITOL

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status

Unknown status

Start Date: February 2006

Completed Date: March 2006

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: A significant correlation between reduced urinary symptoms and a reduction of more than 10 points in the OAB-8 score.

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Ilan Gruenwald, MD

Lead Sponsor: Rambam Health Care Campus

Collaborator: Pfizer

More information:https://clinicaltrials.gov/show/NCT00313924

Corcos J, Schick E. Prevalence of overactive bladder and incontinence in Canada. Can J Urol. 2004 Jun;11(3):2278-84.

Discuss Tolterodine